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Summary Modulation of cell growth by a combination of pravastatin [a 3-hydroxy-3-methylglutaryl-
coenzyme A (HMG-CoA) reductase inhibitor] and d-limonene (an inhibitor of protein isoprenylation) was
studied using Hep G2, a human hepatoma-derived cell line. Pravastatin, at 0.1 mm, produced 85% inhibition
of cholesterol biosynthesis in Hep G2 cells. The combination of 0.1 mm pravastatin and 1.0 mm d-limonene
had no further effect on the reduction seen with pravastatin alone. Addition of 0.1 mM pravastatin or 1.0 mM
d-limonene did not significantly suppress DNA synthesis by the cells, whereas the combination suppressed it to
50% of the control level. Production of m-p2lras was markedly decreased to 35% of the control level by the
combination of these two inhibitors. Both the reduction by pravastatin of farnesylpyrophosphate as substrate
for protein:farnesyl transferase and inhibition of protein farnesylation by d-limonene seem to be responsible
for the profound suppression of m-p21ras formation in the cells. However, dolichol synthesis was not
suppressed by the combination of these inhibitors. In human fibroblasts, the combination suppressed m-p2lras
production but not DNA synthesis. These findings suggest that the combination of pravastatin and d-limonene
acts on cancer cell growth through inhibition of the post-translational processing of cellular proteins including
p2lras, rather than through the suppression of cholesterol and dolichol biosynthesis. Thus, the combination of
an HMG-CoA reductase inhibitor and an inhibitor of protein isoprenylation offers potential as a new
approach for cancer therapy.
The activity of 3-hydroxy-3-methylglutaryl-coenzyme A
(HMG-CoA) reductase [mevalonate NADP:oxidoreductase
(CoA-acylating), EC 1.1.1.34], the major rate-limiting enzyme
in cholesterol biosynthesis, has been suggested to show a
positive correlation with DNA synthesis and growth in mam-
malian cells (Kandutsch & Chen, 1977; Chen, 1981). In
addition to serving as a precursor of the structural
cholesterol required for cell proliferation, the mevalonic acid
produced by HMG-CoA reductase seems to regulate cell
growth independent of cholesterogenesis by playing a direct
role in DNA synthesis (Quesney-Huneeus et al., 1979). Cel-
lular proteins which participate in cell growth regulation,
such as Ras p21 and lamins A and B, have recently been
shown to undergo covalent modification at the carboxyl
terminus by mevalonate-derived farnesyl isoprenoid (Beck et
al., 1988; Wolda & Glomset, 1988; Casey et al., 1989; Han-
cock et al, 1989; Schafer et al., 1989; Goldstein & Brown,
1990).
Manipulation of the mechanisms regulating the mevalon-
ate pathway may offer a new form of therapy for certain
human cancers. In addition to their cholesterol-lowering
activity, HMG-CoA reductase inhibitors (including lova-
statin) exhibit a cytostatic effect when added to cultures of
proliferating cells (Goldstein et al., 1979; Habenicht et al.,
1980; Fairbanks et al., 1984; Maltese, 1984) as well as in vivo
(Maltese et al., 1985). There seem to be three mechanisms
that contribute to the effect of HMG-CoA reductase inhibi-
tors on cell growth: (1) a decrease in the cellular cholesterol
content owing to inhibition of cholesterol biosynthesis, (2) a
reduction of the levels of dolichols and ubiquinones and (3)
inhibition of the isoprenylation processing of cellular proteins
including Ras proteins.
Limonene, the predominant monoterpene in orange peel
oil, has substantial chemopreventive and therapeutic effects
against chemically induced cancers in rodents (Elegbede et
al., 1984; Wattenberg & Coccia, 1991; Crowell, 1992).
Recently, d-limonene was reported to be a selective inhibitor
of the isoprenylation of 21-26 kDa non-nuclear proteins in
intact cells (Crowell et al., 1991). The farnesyl:protein trans-
ferase (FT) that acts on p2l'r is a likely target of d-limonene,
although it has not yet been directly demonstrated that d-
limonene is an inhibitor of FT. However, cell growth was not
suppressed when high concentrations of d-limonene were
added to fibroblast cultures (Crowell et al., 1991). One pos-
sible explanation for this finding is that d-limonene does not
completely block isoprenylation and that subnormal levels of
isoprenylation may be sufficient for a cell growing normally
(Crowell et al., 1991). Thus, the in vivo anti-tumour activity
of limonene could be caused by the greater dependence of
cancer cells on isoprenylated growth control proteins when
compared with normal cells (Crowell et al., 1991). It might
be expected that both reducing farnesyl pyrophosphate (the
substrate for FT) by using HMG-CoA reductase inhibitor
and inhibiting FT itself with d-limonene could strongly sup-
press the farnesylation of proteins, including p21ras, in cancer
cells. Thus, it seems worthwhile to examine whether the
combination of HMG-CoA reductase inhibitor with d-limon-
ene has an augmented effect on protein isoprenylation and
the growth of cancer cells.
The Hep G2 cell line derived from a human hepatocellular
carcinoma shows overexpression of Ras protein with a point
mutation in codon 61 of the N-ras gene (Richards et al.,
1990). The cholesterol metabolism of this cell line has already
been studied in detail (Knowles et al., 1980; Wu et al., 1984;
Hoeg et al., 1985; Erickson & Fielding, 1986). Thus, the Hep
G2 cell line appears to be a good candidate for testing the
growth-inhibitory effect of an HMG-CoA reductase inhibitor
combined with d-limonene. In the present study, to clarify
the effect of both inhibitors on cancer cell growth, we
examined the changes in cholesterol and dolichol biosynthesis
and the changes in the DNA synthesis and membrane-bound
isoprenylated Ras p21 (m-p2l'as) production caused by
pravastatin (Tsujita et al., 1986; Mosley et al., 1989; Reihner
et al., 1990), a potent HMG-CoA reductase inhibitor, and
d-limonene in this cell line. In addition, a comparison was
made with the changes in DNA synthesis and m-p2l'as pro-
duction in human fibroblasts by a combination of both
inhibitors.
Materials and methods
Cellgrowth assay
Hep G2 cells and human skin fibroblasts were maintained in
Dulbecco's modified Eagle medium (DMEM) with 10% fetal
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calf serum in an atmosphere of air + 5% carbon dioxide at
37°C. Cultured fibroblasts were derived from skin biopsy
from a normal subject. The cells were grown in a monolayer
and used between the fifth and 20th passages. To study DNA
synthesis, Hep G2 cells and fibroblasts were cultured at a
density of 3.2 x I03per well in 96-well microplates with
DMEM containing 2% bovine serum albumin (BSA), human
low-density lipoprotein (LDL, 200fig of protein per ml) and
pravastatin (Sankyo, Tokyo) (0, 0.01, 0.1, 1.0 mM) in the
presence or absence of 1 mM d-limonene (Aldrich, >99%
pure by capillary gas chromatography analysis). After 24 h,
[3H]thymidine (1 ytCi per well) was added with or without
aphidicolin (10 jtgml-'). Two hours later, DNA synthesis
was assayed by measuring the incorporation of [3H]thymi-
dine. For determination of cell proliferation, Hep G2 cells
were cultured at a density of 1.5 x I05 cells per 60 mm dish
with the same medium in the presence of pravastatin and/or
d-limonene. After 72 h, cell numbers were determined. Each
assay was carried out in triplicate.
Human LDL (density 1.019-1.063 gml-') was obtained
from the plasma of healthy subjects and prepared by
differential ultracentrifugation according to the method of
Brown et al. (1974).
Assay ofcholesterol and dolichol biosynthesis
The rate of cholesterol biosynthesis from ['4C]acetate was
determined by assaying cholesterol digitonide according to a
modification of the method of Popjak (1969). Hep G2 cells
were cultured for 2 h in 25 cm2 flasks with DMEM contain-
ing 2% BSA, human LDL (200jig of protein per ml), [2-
14C]acetate (0.5fiCi per flask, New England Nuclear) and
pravastatin (0, 0.01, 0.1, or 1.0 mM) in the presence or
absence of 1 mM d-limonene. The cells were harvested with
EDTA (0.02%, w/v) and centrifuged at 1,500 r.p.m. for
10 min. The cell pellet was dissolved in 2 ml of 2 M sodium
hydroxide. After saponification and extraction of the non-
saponifiable components with petroleum ether, an aliquot of
the cholesterol digitonide dissolved in methanol was added to
15 ml of 0.3% 2,5-diphenyloxazole (PPO) and 0.015% bis-
phenyloxazolylbenzene solution in toluene, and the 14C con-
tent was determined with a liquid scintillation counter.
The rate of dolichol biosynthesis from [2-'4C]acetate was
assessed by using a modification of the method for separa-
tion and determination of dolichol with reversed-phase thin-
layer chromatography described by Eggens et al. (1983). Hep
G2 cells were cultured for 2 h with [2-'4C]acetate and 0, 0.01,
0.1 or 1.0 mM pravastatin in the presence and absence of
1 mM d-limonene. After harvesting of cultures, the cell pellet
was dissolved in 2 ml of 2 M sodium hydroxide. Following
saponification and extraction of the non-saponifiable com-
ponents with petroleum ether, the pooled extract was washed
with an equal volume of 1 M sodium chloride. Known
amounts (2.4 nmol) of dolichol-17 and dolichol-23 (Sigma, St
Louis, MO, USA) were added as standards. The petroleum
solvent was evaporated with nitrogen and supplemented with
0.5 ml of Lipidex-5000 and 300 lal of water. A Lipidex-5000
column was prepared by placing acetone-treated Lipidex into
a Pasteur pipette (about 1 cm). Next, the sample was
suspended in Lipidex-acetone-water and was applied to the
column. After washing with methanol, the dolichols were
eluted with 2.5 ml of chloroform-methanol (2:1, v/v) and
were oxidised to alcohols with an oxidising mixture contain-
ing chromium oxide, anhydrous pyridine and dichloro-
methane. After vortexing for 15 s, the reaction was stopped
with methanol, and the test dye-lipophilic mixture for lipid
chromatography (Merck) was added. The sample was then
applied to a silica gel 60 (230-400 mesh, Merck) column
(4 x 0.5 cm) and eluted with 1.5 ml of toluene. The
polyprenol was collected together with the red dye, and the
eluate was evaporated under nitrogen and dissolved in 30yl
of acetone. This sample was applied to a PR-18 HPTLC
plate (Merck), which was developed in pure acetone. After
staining in iodine, the dolichol bands were scraped off to
determine their 14C content with a liquid scintillation
counter.
Sodium dodecyl sulphate (SDS) gel analysis of
post-translationalprocessing ofp2lras
Hep G2 cells or fibroblasts were preincubated for 2 h in
methionine-free DMEM containing 2% BSA, human LDL
(200 jig of protein per ml) and pravastatin (0, 0.01, 0.1, or
1.0mM) in the presence or absence of 1 mM d-limonene or
20 mM mevalonate before incubation with [35S]methionine.
The cells were then incubated for 12 h with [35S]methionine
(100JACiml-, New England Nuclear) in the same medium.
All cells were lysed on ice for 10 min in immunoprecipitation
buffer (50 mM Tris-HCl, pH 7.5, 20 mM magnesium
chloride, 150 mm sodium chloride and 1% aprotinin) con-
taining 1% Triton X-114 and were centrifuged at 10,000 g at
4°C to remove insoluble debris according to a modification of
the method of Gutierrez et al. (1989). The samples were
immunoprecipitated for 16 h at 4°C with an anti-Ras p21
monoclonal antibody (Y13-259, ATCC, 1:50 dilution), using
fresh protein A-Sepharose CL-4B beads (Sigma) precoated
with rabbit anti-mouse IgG. The precipitated beads were
washed twice with washing buffer (50 mM Tris-HCl, pH 7.5,
20 mm magnesium chloride and 150 mM sodium chloride)
and suspended in 20 1I of 20 mM Tris-HCl (pH 7.5)-20 mM
EDTA - 2% SDS. This suspension was incubated at 100°C
for 5 min to elute bound p21l' and was then centrifuged. The
immunoprecipitated Ras proteins were analysed by 8-15%
gradient SDS-PAGE and the "S-labelled proteins on the gels
were identified by fluorography. The bands were excised and
quantiated by liquid scintillation spectrometry.
[35S]Methionine incorporation into p2lras in Hep G2 cells
or fibroblasts was at isotopic equilibrium after 11 h of label-
ling, and there was no change in the specific radioactivity of
p21rcl between 11 and 14 h under incubation conditions.
Therefore, a 12 h labelling period was used to examine the
effect of pravastatin on the cellular level of mature p21ral.
Other assays
The free and esterified cholesterol contents in Hep G2 cells
were determined using methods described previously (Kawata
et al., 1987, 1990). The protein content of the cells was
determined by the method of Lowry et al. (1951).
Statistical analysis
Statistical analysis was done using Student's t-test.
Results
Pravastatin decreased the rate of cholesterol biosynthesis in
Hep G2 cells in a dose-dependent manner in the absence of
d-limonene in the culture medium (Figure 1). Addition of
1.0 mM d-limonene did not alter the degree of suppression of
cholesterol biosynthesis by 0.01, 0.1 and 1.0 mM pravastatin.
Addition of 1.0 mM pravastatin suppressed cholesterol
biosynthesis to less than 10% of the control value both in the
presence and absence of d-limonene. The cholesterol content
was decreased in a dose-dependent manner by the addition of
pravastatin to Hep G2 cultures, and the cholesterol content
was not altered any further by the addition of d-limonene
(Figure 2).
DNA synthesis by Hep G2 cells was decreased in a dose-
dependent manner by the addition of pravastatin in the
absence of d-limonene (Figure 3). Pravastatin did not
significantly suppress DNA synthesis at 0.1 mM, but sup-
pressed it to approximately 70% of the control value at
1.0 mM. Pravastatin also suppressed the cell number to ap-
proximately 30% of the control value at 1.0 mM. The con-
centration dependence of the inhibition of dolichol synthesis
was similar to that for m-p21ras, while cholesterol biosyn-
thesis was inhibited by a much lower concentration ofCELL GROWTH MODULATION BY PRAVASTATIN AND d-LIMONENE 1017
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Figure 1 Effect of pravastatin on cholesterol biosynthesis from
["4C]acetate in Hep G2 cells in the presence (0) and absence (@)
of 1.0 mm d-limonene. Each value represents the average of
triplicate samples.
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pravastatin. The concentration dependence of the suppres-
sion of DNA synthesis paralleled that of m-p21ras or dolichol
synthesis.
DNA synthesis by Hep G2 cells was decreased in a dose-
dependent manner by the addition of d-limonene in the
absence of pravastatin (Figure 4). d-Limonene did not
significantly suppress DNA synthesis at 1.0-2.0 mM d-
limonene, while 3.0 and 4.0 mM d-limonene suppressed DNA
synthesis to approximately 50 and 20%, respectively, of the
control value. d-Limonene at 3.0 and 4.0 mM suppressed the
cell number to approximately 25 and 10%, respectively, of
the control value. The concentration dependence of the sup-
pression of DNA synthesis paralleled that of m-p21' syn-
thesis.
The effect of a combination of pravastatin and d-limonene
on DNA synthesis, m-p21l' production and dolichol syn-
thesis was then examined in Hep G2 cells (Figures 5 and 6).
Addition of either 0.1 mM pravastatin or 1.0 mM d-limonene
to the culture medium did not significantly suppress DNA
synthesis, whereas a combination of 0.1 mM pravastatin and
1.0 mM d-limonene suppressed it to approximately 50% of
the control level. Addition of either 0.1 mM pravastatin or
1.0 mM d-limonene did not significantly suppress the cell
proliferation, whereas the combination suppressed the cell
number to approximately 35% of the control value
(1.51 x 105 per dish vs 4.32 x 105 per dish, the average of
triplicate samples). Production of m-p21ras was markedly
decreased to approximately 35% of the control level by the
combination of both inhibitors. In contrast, dolichol syn-
thesis was not significantly suppressed by the combination of
both inhibitors.
To test the effect of a combination of pravastatin and
d-limonene in non-transformed cells, we examined the effect
on DNA synthesis and m-p21'as production in human fibro-
blasts (Figure 7). Addition of either 0.1 mM pravastatin or
1.OmM d-limonene to the culture medium did not signifi-
cantly suppress DNA synthesis in the fibroblasts, while their
combination suppressed production ofm-p21ras but not DNA
synthesis.
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Figure 2 Cholesterol content of Hep G2 cells in the presence
(0) and absence (M) of 1.0 mM d-limonene. a, Total cholesterol
content; b, Esterified cholesterol content. Each value represents
the average of triplicate samples.
Discussion
HMG-CoA reductase inhibitors effectively suppressed choles-
terol biosynthesis in mammalian cells (Endo et al., 1976;
Alberts et al., 1980). Since mevalonic acid, the product of the
reaction catalysed by HMG-CoA reductase, is required for
the biosynthesis of a number of cellular isoprenoids (Gough
& Hemming, 1970; Martin & Thorne, 1974; Faust et al.,
1979; Nambudiri et al., 1980), inhibition of this enzyme can
result in suppression of the synthesis of various other
compounds. A notable class of endogenously synthesised
isoprenoids are the isoprenylated substituents post-trans-
lationally incorporated into cellular proteins, such as Ras p21
and lamins (Beck et al., 1988; Wolda & Glomset, 1988; Casey
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Figure 3 Concentration dependence of the inhibition of choles-
terol (0) and dolichol (A) biosynthesis, m-p2lras formation (0)
and DNA synthesis (A) in Hep G2 cells by pravastatin. Each
value represents the average of triplicate samples.
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Figure 4 Concentration dependence of the inhibition of m-p21'
formation (0) and DNA synthesis (A) in Hep G2 cells by
d-limonene. Each value represents the average of triplicate
samples.
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et al., 1989; Hancock et al., 1989; Schafer et al., 1989;
Goldstein & Brown, 1990).
Pravastatin, a potent HMG-CoA reductase inhibitor,
decreased cholesterol biosynthesis in Hep G2 cells in a dose-
dependent manner in the present study. Addition of 0.1 mM
pravastatin suppressed cholesterol biosynthesis to 15% of the
control level. The concentration at which pravastatin sup-
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Figure 5 SDS gel analysis of the effect of a combination of
pravastatin and d-limonene on the post-translational processing
of Ras p21 protein in Hep G2 cells. p, pro-p21ral, m, m-
p21ras.
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pressed cholesterol biosynthesis in Hep G2 cells was much
higher than those reported previously for lovastatin and
simvastatin (Shaw et al., 1990).
The dramatic effect of pravastatin on cholesterol biosyn-
thesis in Hep G2 cells appeared to be inconsistent with the
fairly modest effects on cellular contents of total and
esterified cholesterol. However, several investigations in vitro
and in vivo showed that HMG-CoA reductase inhibitors
including pravastatin can induce binding activity of LDL
receptors and thus supply exogenous cholesterol to the
cholesterol-depleted cells (Brown et al., 1981; Kovanen et al.,
1981; Reihner et al., 1990). It is likely that the Hep G2 cells
treated with pravastatin could enhance the uptake of LDL-
cholesterol in the medium through an increased binding
activity of LDL receptors, although the binding activity was
not examined in this study.
Inhibition of the formation of m-p21ras and dolichols by
pravastatin occurred at similar concentrations in Hep G2
cells, whereas cholesterol biosynthesis was inhibited at a
much lower concentration. Sinensky et al. (1990) studied a
Chinese hamster ovarian cell line and HeLa cells and demon-
strated that the degree of inhibition of HMG-CoA reductase
by lovastatin that was required to completely block the for-
mation of m-p2lr' and lamin A was much greater than that
required for 50% inhibition of cholesterol synthesis. In this
study, we found that the pravastatin concentration inhibiting
dolichol biosynthesis was similar to that inhibiting the forma-
tion of m-p2Ir,. A possible explanation for the relative in-
sensitivity of isoprenylated protein synthesis to the inhibition
of mevalonate biosynthesis is that the Km for the farnesyl-
pyrophosphate substrate of prenyl transferase is substantially
lower than that for squalene synthase (Sinensky et al., 1990).
It has been reported that, in the case of the prenyl trans-
ferase, which forms dolichol pyrophosphate, the Km value for
farnesylphosphate is lower than that for squalene synthase,
thus allowing the synthesis of isoprenoids despite the partial
inhibition of mevalonate biosynthesis (James & Kandutsch,
1979).
DNA synthesis in Hep G2 cells was suppressed in parallel
with the inhibition of m-p21rl' formation by 0.01, 0.1 and
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Figure 6 Effect of a combination of pravastatin and d-limonene
on DNA synthesis, m-p21 ras formation and dolichol biosynthesis
in Hep G2 cells. P, 0.1 mM pravastatin; L, 1.0 mM d-limonene;
P + L, 0.1 mm pravastatin plus 1.0 mm d-limonene. Mean values
of triplicate cultures ± s.e. are shown for each condition.
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Figure 7 Effect of a combination ofparavastatin and d-limonene
on DNA synthesis and m-p2 ras formation in human fibroblasts.
P, 0.1 mM pravastatin; L, 1.0 mM d-limonene, P + L, 0.1 mM
pravastatin plus 1.0 mm d-limonene. Mean values of triplicate
cultures ± s.e. are shown for each condition.
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1.0 mM pravastatin. This observation raises the possibility
that the growth inhibition of Hep G2 cells by pravastatin
might have been related to suppression of isoprenylation of
the activated N-Ras protein with a point mutation, although
there is still no direct evidence that N-ras activation is
required for the growth of these cells. Mendola and Backer
(1990) showed that N-ras oncogene-induced neuronal differ-
entiation of UR61J rat phaeochromocytoma cells is blocked
by lovastatin. However, Declue et al. (1991) demonstrated,
using a series of NIH3T3 cell lines transformed by onco-
genes, including v-ras and c-ras, that inhibition of cell growth
by lovastatin was not specific for cells in which transforma-
tion was dependent upon isoprenylated Ras proteins. Thus,
the-HMG-CoA reductase inhibitors seem to modulate diverse
cellular functions through their suppression of isoprenoid
formation and thus inhibit cell growth.
In this study, we examined the inhibitory effect of the
combination of pravastatin and d-limonene, a selective
inhibitor of protein isoprenylation, on the mevalonate path-
way and cell growth. The combination of 0.1 mM pravastatin
and 1.OmM d-limonene suppressed DNA synthesis to app-
roximately 50% of the control level in Hep G2 cells, whereas
0.1 mM pravastatin and 1.0 mM d-limonene alone did not
significantly suppress DNA synthesis. The combination of
pravastatin and d-limonene had no further effect on the
reduction of cholesterol biosynthesis seen with pravastatin
alone. This finding agreed with the report of Crowell et al.
(1991) that a combination of d-limonene and simvastatin, an
HMG-CoA reductase inhibitor, had no further effect on
reduction of cholesterol biosynthesis in NIH3T3 cells seen
with simvastatin alone. In addition, the combination of
0.1 mM pravastatin and 1 mM d-limonene did not signifi-
cantly suppress dolichol biosynthesis by Hep G2 cells. These
observations suggest that the inhibitory effect of the com-
bination of 0.1 mM pravastatin and 1.0 mM d-limonene on
the growth of Hep G2 cells was not derived from the deple-
tion of cellular cholesterol or the inhibition of dolichol
biosynthesis.
The combination of pravastatin and d-limonene suppressed
m-p2lraz formation to less than 50% of the control level,
whereas pravastatin or d-limonene alone did not significantly
affect it. HMG-CoA reductase inhibitors suppress the pro-
duction of farnesylpyrophosphate and geranylgeranylpyro-
phosphate, which are isoprenylated substitutents that are
post-translationally incorporated into cellular proteins in-
cluding Ras p21 and lamins. On the other hand, Crowell et
al. (1991) showed that d-limonene does not affect the
prenylation of nuclear proteins including lamins, but instead
selectively affects the prenylation of 21-26 kDa non-nuclear
proteins including Ras p21. Thus, both the reduction of
farnesylpyrophosphate as substrate for FT and inhibition of
FT itself by d-limonene seem to be responsible for the pro-
found suppression of the formation of m-p2lras in Hep G2
cells. Very recent studies demonstrated that lamin processing
is less sensitive than Ras p21 processing to inhibition by
known inhibitors of FT (Garcia et al., 1993; James et al.,
1993).
The combination of both inhibitors suppressed m-p2lrzs
production in human fibroblasts but not DNA synthesis.
Pravastatin decreased the rate of cholesterol biosynthesis in
human fibroblasts in a similar manner to that in Hep G2
cells, and the combination of both inhibitors had no further
effect on the reduction in the fibroblasts (data not shown).
Our observations suggest that the reduction of protein
isoprenylation by the combination of both inhibitors sup-
pressed DNA synthesis in cancer cells but not in non-
transformed cells. This implies that subnormal levels of
isoprenylated growth control proteins may be sufficient for
the proliferation of non-transformed cells. The combination
of an HMG-CoA reductase inhibitor and an inhibitor of
protein isoprenylation may offer a new approach to cancer
chemotherapy.
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